Skip to main content
Thiogenesis Therapeutics, Corp. logo

Thiogenesis Therapeutics, Corp. — Investor Relations & Filings

Ticker · TTI ISIN · CA88410L1022 LEI · 9845006CBA639FFD6454 TSXV Manufacturing
Filings indexed 208 across all filing types
Latest filing 2026-05-11 Regulatory Filings
Country CA Canada
Listing TSXV TTI

About Thiogenesis Therapeutics, Corp.

https://www.thiogenesis.com/

Thiogenesis Therapeutics, Corp. is a clinical-stage biotechnology company specializing in the development of New Chemical Entities (NCEs), specifically novel thiol-based prodrugs. These next-generation sulfur-containing therapeutics are designed to restore redox balance and mitigate inflammation, key drivers in inherited and acquired mitochondrial diseases. The company's lead candidate, TTI-0102, is a novel cysteamine prodrug engineered to overcome the limitations of legacy thiol therapies, offering enhanced tolerability, bioavailability, and improved dosing profiles. TTI-0102 is currently being evaluated for unmet pediatric medical needs, including nephropathic cystinosis (with a pivotal Phase 3 trial planned following an expected 2026 IND filing), MELAS (in Phase 2), and other conditions such as Leigh syndrome spectrum.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings
2026-05-11 English
ON form 13-502F1 (class 1 and 3B reporting issuers - participation fee).PDF
Regulatory Filings
2026-04-30 English
52-109FV1 - Certification of annual filings - CEO (E).pdf
Regulatory Filings
2026-04-30 English
Annual MD&A - English.pdf
Regulatory Filings
2026-04-30 English
News release - English.pdf
Investor Presentation Classification · 94% confidence The document is a corporate press release announcing that the company’s management will present at an upcoming healthcare investor conference, including date, time, presenters, and overview of the presentation. It is not actual financial results, an AGM or proxy, nor a regulatory notice of share transactions or legal matter. This is an announcement of an investor presentation event. Therefore, it falls under Investor Presentation (IP).
2026-04-16 English
News release - English.pdf
Regulatory Filings Classification · 80% confidence The document is a company press release announcing that management will present at an upcoming healthcare investor conference. It does not provide actual presentation slides (Investor Presentation), detailed financial results (Earnings Release or Interim Report), nor is it a formal annual/quarterly report. It is an announcement to the market/disclosure of an investor event. Since there is no specific category for press releases, it falls under the general “Regulatory Filings” fallback category (RNS).
2026-04-16 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.